IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Purpose

Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) has been shown in clinical trials, registries, and meta-analyses to reduce recurrent events after PCI. This is accomplished by improving the angiographic result with lesion and vessel assessment to guide stent selection and implantation and intravascular imaging following stent implantation to ensure an adequate treatment endpoint has been achieved. Despite extensive literature supporting the use of IVUS in PCI, utilization remains low in the United States. An increasing number of high-risk or complex lesions are being treated with PCI and we hypothesize that the impact of IVUS in these complex lesions will be of increased importance in reducing clinical adverse events while remaining cost effective.

Condition

  • Atherosclerosis

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 years at screening - PCI with stent implantation involving a high risk or complex lesion defined as involving at least one of the following characteristics: - Chronic total occlusion - In-stent restenosis - Severe coronary artery calcification - Long lesion (≥ 28 mm in length) - Bifurcation lesion (Any Medina class that involves main branch disease with a side branch ≥2.0 mm) - Stable angina, unstable angina, or non-ST Elevation myocardial infarction (NSTEMI), undergoing PCI of a single or multivessel coronary artery stenosis - PCI performed with either angiography alone, or IVUS guidance used

Exclusion Criteria

  • Subjects with acute ST elevation myocardial infarction (STEMI), or cardiogenic shock - Use of fibrinolytic therapy within 24 hours of PCI - Planned revascularization of a target vessel as a staged procedure - Stent thrombosis - Use of optical coherence tomography (OCT) during the index procedure

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Single (Participant)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
IVUS guided PCI 		Patients will receive a pre-PCI IVUS, IVUS guided stent sizing and optimization per study protocol, post-PCI IVUS
  • Device: Eagle Eye Platinum digital IVUS catheter with optional SyncVision
    IVUS catheter
  • Device: Resolute Onyx Drug Eluting Stent
    Stent
  • Device: Onyx Frontier Drug Eluting Stent
    Stent
  • Device: Onyx TruStar Drug Eluting Stent
    Stent
  • Device: Onyx TruCor Drug Eluting Stent
    Stent
Placebo Comparator
Angiographic-guided PCI 		Patients will receive angiography guided PCI and angiographic optimization per local standard practice, as well as a post-PCI IVUS blinded to the investigator
  • Device: Resolute Onyx Drug Eluting Stent
    Stent
  • Device: Onyx Frontier Drug Eluting Stent
    Stent
  • Device: Onyx TruStar Drug Eluting Stent
    Stent
  • Device: Onyx TruCor Drug Eluting Stent
    Stent

Recruiting Locations

Massachusetts General Hospital
Boston, Massachusetts 02114
Contact:
Darshan Doshi
Darshan_Doshi@MGH.HARVARD.EDU

More Details

Status
Recruiting
Sponsor
Medstar Health Research Institute

Study Contact

Shreejana Pokharel
2409417922
shreejana.pokharel@medstar.net

Detailed Description

This is a prospective, single-blind clinical investigation randomizing subjects to IVUS-guided coronary stent implantation vs. angiography-guided coronary stent implantation in a 1:1 ratio. The clinical investigation will be conducted at approximately 120 centers in the US, Canada, and Europe. Approximately 2,500-3,100 randomized subjects and up to 3 roll-in subjects per site will be enrolled in this study. Subjects participating in this clinical investigation will be followed for 2 years. The expected duration of enrollment is approximately 2.5 years. The total duration of the clinical investigation is expected to be approximately 4.5 years.